Gastrointestinal Stromal Tumour — Soft Tissue GI Sarcoma

Histologically, a gastrointestinal stromal tumour arises from the interstitial cells of Cajal, or their precursor stem cells, situated within the muscular layers of the gastrointestinal wall. Unlike adenocarcinomas, which originate in the mucosal surface lining, GISTs expand outward into the abdominal cavity or inward from the deeper wall layers as mesenchymal neoplasms.

At the molecular level, approximately eighty-five percent of GISTs are driven by mutually exclusive gain-of-function mutations in either the KIT proto-oncogene or the platelet-derived growth factor receptor alpha (PDGFRA) gene. These genetic alterations lead to continuous, ligand-independent activation of receptor tyrosine kinases, triggering uncontrolled intracellular signalling cascades that drive tumour cell survival, proliferation, and resistance to natural programmed cell death.

Recognizing a tumour as a GIST rather than a typical digestive carcinoma is vital because GISTs do not respond to conventional cytotoxic chemotherapy or standard pelvic/abdominal radiation. Instead, they represent one of modern oncology's greatest targeted therapy successes. Determining whether your tumour has spread, evaluating its mitotic rate (how fast cells divide), measuring its size, and identifying its exact genetic mutation dictate your prognosis and whether you will benefit from targeted medication before or after surgery.

Diagnosis requires formal tissue sampling via endoscopic ultrasound-guided fine-needle biopsy or surgical resection. Pathologists confirm GIST using immunohistochemical staining for CD117 (the protein product of the KIT gene) and DOG1 (Discovered on GIST-1). Once GIST is diagnosed, molecular mutational testing via next-generation sequencing is essential to identify the specific mutation in KIT (frequently exon 9, 11, 13, or 17) or PDGFRA (such as the D842V mutation).

GISTs can occur anywhere along the alimentary canal from the oesophagus to the anus. The stomach is the most frequent site of presentation (accounting for roughly sixty percent of cases), followed by the small intestine (jejunum and ileum, roughly thirty percent). Less commonly, GISTs develop in the colon, rectum, or duodenum, and very rarely arise in extragastrointestinal sites such as the omentum, mesentery, or retroperitoneum.

Localized GISTs are managed primarily with complete surgical resection, avoiding lymph node dissection because GISTs rarely spread to lymph nodes. For patients with high-risk features, adjuvant therapy with the tyrosine kinase inhibitor imatinib is prescribed for three years to lower recurrence risks. In advanced or metastatic disease, oral targeted agents—including imatinib, sunitinib, regorafenib, and ripretinib—serve as sequential standard treatments, matched carefully against the tumour's mutational profile.